PedAM
Pediatric Disease Annotations & Medicines
| Disease | hypogonadism |
| Phenotype | C0011847|diabetes |
| Sentences | 16 |
| PubMedID- 22514541 | These data indicate that testosterone replacement may be important to reduce cardiovascular risk factors, especially in type 2 diabetes associated with the hypogonadism condition. |
| PubMedID- 26417412 | Studies have confirmed that the glycemic control, insulin resistance, obesity and osteoporosis of male type 2 diabetes patients with hypogonadism were improved after hormone replacement therapy25. |
| PubMedID- 22211848 | Prevalence of late-onset hypogonadism in men with type 2 diabetes mellitus. |
| PubMedID- 21982717 | Aim: there is increasing awareness of hypogonadism in men with type 2 diabetes but limited data from primary care. |
| PubMedID- 21386088 | The beneficial effects of trt on overall sexual function and, importantly, libido (a key symptom of testosterone deficiency) support the assessment and treatment of hypogonadism in men with type 2 diabetes and/or mets who do not present specifically with erectile dysfunction. |
| PubMedID- 20150021 | Treatment of hypogonadism with testosterone in patients with type 2 diabetes mellitus. |
| PubMedID- 21709300 | In addition, hypogonadism in men with type 2 diabetes was associated with decreased sexual desire, more symptoms of depression, and lower luteinizing hormone levels. |
| PubMedID- 24914264 | Aps ii consists of addison's disease plus either an autoimmune thyroid disease or type i diabetes mellitus associated with hypogonadism, pernicious anemia, celiac disease, recent primary biliary cirrhosis, myasthenia gravis, parkinson disease, vitiligo, alopecia and seronegative arthritis. |
| PubMedID- 24222915 | hypogonadism can be associated with diabetes per se, but vascular factors, drugs, tobacco, alcohol, and systemic diseases such as hypertension, heart diseases, and dyslipidemia can be risk factors of testosterone deficiency. |
| PubMedID- 25394376 | Introduction: the prevalence of hypogonadotropic hypogonadism (hh) in patients with type 2 diabetes mellitus is higher than in the general population and leads to detrimental effects on metabolic control, lipid profile, and body composition. |
| PubMedID- 24615662 | This raises the possibility that diminished kisspeptin secretion is a potential mechanism for hypogonadotropic hypogonadism in patients with obesity and diabetes (george et al., 2010). |
| PubMedID- 20585348 | Diagnosis: lymphocytic hypophysitis presenting with diabetes insipidus, with development of hypogonadotropic hypogonadism and a suprasellar mass. |
| PubMedID- 23798917 | [5–1113] our study has shown that the prevalence of hypogonadism in men with type 2 diabetes is high, especially, if it was defined based on calculated free and bioavailable testosterone. |
| PubMedID- 23869290 | Physicians should screen for hypogonadism in men with diabetes, while understanding that this condition affects much more than sexuality. |
| PubMedID- 23153270 | Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and lh secretion in men with type 2 diabetes and mild biochemical hypogonadism. |
| PubMedID- 23970784 | Male hypogonadism associates with type 2 diabetes, and t can protect pancreatic beta-cells from glucotoxicity. |
Page: 1